AMBITION
Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 500 patients with pulmonary arterial hypertension, initial ambrisentan plus tadalafil reduced clinical-failure events compared with monotherapy.
N
500
Design
Double-blind RCT
Endpunkt
First clinical-failure event
Relevanz
1
ErgebnisHR 0.50 for the primary composite.
Galiè N, et al. N Engl J Med. 2015;373(9):834-844. 10.1056/NEJMoa1413687
Diskussion & Kritik
Established upfront dual combination therapy as the standard initial approach for most patients with PAH.